Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CODEXIS, INC.CDXS · Entity 6428 | Director | June 17, 2026 | June 18, 2026 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 10, 2020 | January 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CODEXIS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17 | Direct | 66,350 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.
Coherus Oncology, Inc.
Report date January 10, 2020 · Filed January 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.73 · Expires 2030-01-10 | Direct | 20,000 |
Reported balance
After 2020-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-10 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:56 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 66,350 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001610717-26-000271 · form4.xml · derivative · entry 1 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,350 Underlying: Common Stock · 66,350 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 23:29 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 40,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002132 · form4.xml · nonDerivative · entry 1 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,133 F1 · shares: The restricted stock units vest as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:28 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 44,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000132 · form4.xml · nonDerivative · entry 1 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,150 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:52 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001043 · doc1.xml · derivative · entry 1 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2019 Filed Jan 30, 2019 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-002185 · doc4.xml · derivative · entry 2 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002880 · doc4.xml · derivative · entry 2 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.80 | $0.00 |
DisclosureSEC source: 0000899243-17-013889 · doc4.xml · derivative · entry 2 Richards Christos · CIK 0001622055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.